Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Conference Highlights Report: Therapy of Hepatitis C: Clinical Application and Drug Development

EASL and AASLD co-organised a Special Conference on Therapy of Hepatitis C: Clinical Application and Drug Development, in Prague in September 2012. The report of the meeting is now available online.

Published
02 October 2012
From
EASL
Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents

Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.

Published
27 September 2012
From
HIVandHepatitis.com
Ethics of hepatitis C drug pitch questioned

Ethicists said that the doctor's comments appear to have breached ethics principles by potentially leaving his audience with outsize hope for drugs undergoing testing. Doing so, they said, was particularly striking at a moment when patients felt violated and vulnerable.

Published
25 September 2012
From
Boston Globe
Simeprevir (TMC435) and TMC647055 Interferon Free Combination Hepatitis C Trial Will Commence Shortly

Medivir AB (OMX: MVIR), announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial. Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III clinical development for the treatment of chronic hepatitis C jointly developed by Medivir and Janssen Research & Development Ireland (Janssen). TMC647055 is a potent NNI (non-nucleoside inhibitor) of the HCV NS5B polymerase and is being developed by Janssen R&D.

Published
21 September 2012
From
Medivir press release
Boehringer Ingelheim exits virology research as hep C drugs move down pipeline

Boehringer Ingelheim is ending its virology research programme. The company's best-known products in virology are the antivirals Aptivus (tipranavir) and Viramune (nevirapine) which have been on the market for a long time as AIDS treatments. It is also been working on two oral drugs for hepatitis C, namely BI 201335, an NS3/4A protease inhibitor in Phase III and BI 207127, an NS5B RNA-dependent polymerase inhibitor in Phase II.

Published
20 September 2012
From
Pharma Times
Switching to tenofovir suppresses hepatitis B in HIV/HBV co-infected people

People with HIV and hepatitis B virus (HBV) co-infection, who substituted tenofovir (Viread) for zidovudine (Retrovir) or abacavir (Ziagen) in their antiretroviral regimen, saw a reduction in hepatitis

Published
20 September 2012
By
Liz Highleyman
Medgenics' Bulging Pipeline Of Blockbuster Indications Takes On Big Pharma's Harmful Drugs

The beauty of Medgenics's technology is that it uses an old standard for hepatitis C - interferon - but as the body's natural protein. PEG-interferon sold today has what is basically a string of nylon molecules attached to the protein that is then injected into the bloodstream. The side effects make Lou Gehrig's disease look like a day at the beach.

Published
19 September 2012
From
Seeking Alpha
Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers

Brian Starkey didn't have insurance coverage when he was diagnosed with hepatitis C. So when a doctor pointed him to a study of Bristol-Myers Squibb's experimental BMS-094, he leaped at a chance to get free care.

Published
18 September 2012
From
Fierce Biotech
Sofosbuvir appears safe and effective for HIV/HCV co-infected people

HIV/HCV co-infected people taking the experimental hepatitis C virus polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV-negative

Published
13 September 2012
By
Liz Highleyman
Bacterial translocation is associated with more severe liver fibrosis in HIV/hepatitis C-co-infected people

The presence of intestinal bacteria in blood (bacterial translocation) is associated with more severe liver disease in people who are co-infected with HIV and hepatitis C virus,

Published
13 September 2012
By
Michael Carter

Filter by country